| Name | Sareum Holdings |
|---|---|
| Epic | SAR |
| Isin | GB00BMC3RJ87 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 22.00p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £27.48 | Debt ratio | n/a |
| Shares in issue | 125.28 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -219.21 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -4.2 | 52-week high / low | 10.25p / 53.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Sareum Holdings |
|---|---|
| Address | Unit 2A, Langford Arch,London Road, Pampisford, Cambridge, Cambridgeshire, United Kingdom, CB22 3FX |
| Telephone | +44 (0) 1223 497700 |
| Website | http://www.sareum.co.uk |
| Director | Position |
|---|---|
| Dr Timothy J Mitchell | COO |
| Mr Michael Owen | Non-Executive Director |
| Mr Clive Birch | Non-Executive Director |
| Dr John C Reader | Executive Director |
| Dr Stephen Parker | Non-Executive Chairman |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 30/06/24 | 30/06/23 | 30/06/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | 0.01 | 0.05 | 0.02 |
| Total non-current assets | 0.01 | 0.05 | 0.03 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 1.3 | 0.98 | 0.5 |
| Cash and equivalents | 1.46 | 0.99 | 4.26 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 2.77 | 2.02 | 4.79 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.65 | 0.87 | 0.46 |
| Long term liabilities | n/a | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.65 | 0.87 | 0.46 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 2.11 | 1.15 | 4.33 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 1.35 | 0.85 | 0.85 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -24.37 | -20.96 | -17.77 |
| Share premium account | 24.8 | 20.93 | 20.93 |
| Total equity | 2.11 | 1.15 | 4.33 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -4.63 | -4.07 | -2.58 |
| Pre-tax profit | -4.6 | -4.03 | 2.58 |